Mouh Fatima Zahra, Mzibri Mohammed El, Slaoui Meriem, Amrani Mariam
Equipe deRecherche ONCOGYMA, University of Mohamed V, Faculty of Medicine and Pharmacy of Rabat Morocco E-mail :
Asian Pac J Cancer Prev. 2016;17(4):1595-608. doi: 10.7314/apjcp.2016.17.4.1595.
Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. Recently, important molecular characteristics of TNBC have been highlighted and led to the identification of some biomarkers that could be used in diagnosis, as therapeutic targets or to assess the prognosis. In this review, we summarize recent progress in TNBC research focusing on the genetic and epigenetic alterations of TNBC and the potential use of these biomarkers in the targeted therapy for better management of TNBC.
三阴性乳腺癌（TNBC）被定义为一种雌激素和孕激素受体（ER、PR）以及HER2表达均为阴性的乳腺癌。这种形式的乳腺癌具有侵袭性强、生存率低且缺乏特异性治疗方法的特点。最近，TNBC的重要分子特征已得到突出强调，并导致鉴定出一些可用于诊断、作为治疗靶点或评估预后的生物标志物。在本综述中，我们总结了TNBC研究的最新进展，重点关注TNBC的基因和表观遗传改变以及这些生物标志物在靶向治疗中用于更好地管理TNBC的潜在用途。
